{"title":"基于细胞疗法治疗压力损伤的进展:介入研究的系统回顾。","authors":"Alianda Camesi, Reto Wettstein, Ezra Valido, Nicole Nyfeler, Stevan Stojic, Marija Glisic, Jivko Stoyanov, Alessandro Bertolo","doi":"10.1177/20417314231201071","DOIUrl":null,"url":null,"abstract":"<p><p>The high recurrence and complications associated with severe pressure injuries (PI) necessitate the exploration of advanced treatments, such as cell-based therapies, to facilitate wound healing. Such techniques harness the ability of different cell types to promote angiogenesis, re-epithelialization of the skin, and tissue regeneration. This systematic review explores the efficacy of cell-based therapies and tissue engineering in treating deep PI. We searched for interventional studies using cells in the treatment of PI in adults in four online libraries (PubMed, Embase, Ovid Medline, and Cochrane; latest search 10th June 2023). We found one randomized clinical trial (RCT), two non-RCT, and three pre-post studies, comprising 481 study participants with PI (253 intervention/228 controls). The risk of bias was categorized as moderate due to minimal bias in outcome measurements, or high owing to unclear patient randomization methods, as assessed by the ROBINS-I, NIH, and RoB-2 tools. Four cell types were identified in the context of cell-based therapies of PI: bone marrow mononuclear stem cells (BM-MNCs, <i>n</i> = 2); hematopoietic derived stem cells (HSC, <i>n</i> = 1); macrophages and activated macrophage suspensions (AMS, <i>n</i> = 2); and cryopreserved placental membrane containing viable cells (vCPM, <i>n</i> = 1). Wound healing outcomes were observed in patients undergoing cell-based therapies, including complete wound closure (AMS, vCPM; <i>n</i> = 142), faster healing rate (BM-MNCs, AMS; <i>n</i> = 146), improved granulation tissue formation (HSC, <i>n</i> = 3) and shorter hospitalization time (BM-MNCs; <i>n</i> = 108) compared to standard of care, with no adverse reactions. PI healing rate decreased only in one study with BM-MNC therapy, compared to control (<i>n</i> = 86). Based on the available data, though with limited evidence, it seems that macrophage deployment showed the most favorable outcomes. The results indicate that cell-based therapies offer a potential avenue for enhancing wound healing and tissue repair in PI; however, more extensive research is needed in this domain.</p>","PeriodicalId":17384,"journal":{"name":"Journal of Tissue Engineering","volume":"14 ","pages":"20417314231201071"},"PeriodicalIF":6.7000,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658773/pdf/","citationCount":"0","resultStr":"{\"title\":\"Advancements in cell-based therapies for the treatment of pressure injuries: A systematic review of interventional studies.\",\"authors\":\"Alianda Camesi, Reto Wettstein, Ezra Valido, Nicole Nyfeler, Stevan Stojic, Marija Glisic, Jivko Stoyanov, Alessandro Bertolo\",\"doi\":\"10.1177/20417314231201071\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The high recurrence and complications associated with severe pressure injuries (PI) necessitate the exploration of advanced treatments, such as cell-based therapies, to facilitate wound healing. Such techniques harness the ability of different cell types to promote angiogenesis, re-epithelialization of the skin, and tissue regeneration. This systematic review explores the efficacy of cell-based therapies and tissue engineering in treating deep PI. We searched for interventional studies using cells in the treatment of PI in adults in four online libraries (PubMed, Embase, Ovid Medline, and Cochrane; latest search 10th June 2023). We found one randomized clinical trial (RCT), two non-RCT, and three pre-post studies, comprising 481 study participants with PI (253 intervention/228 controls). The risk of bias was categorized as moderate due to minimal bias in outcome measurements, or high owing to unclear patient randomization methods, as assessed by the ROBINS-I, NIH, and RoB-2 tools. Four cell types were identified in the context of cell-based therapies of PI: bone marrow mononuclear stem cells (BM-MNCs, <i>n</i> = 2); hematopoietic derived stem cells (HSC, <i>n</i> = 1); macrophages and activated macrophage suspensions (AMS, <i>n</i> = 2); and cryopreserved placental membrane containing viable cells (vCPM, <i>n</i> = 1). Wound healing outcomes were observed in patients undergoing cell-based therapies, including complete wound closure (AMS, vCPM; <i>n</i> = 142), faster healing rate (BM-MNCs, AMS; <i>n</i> = 146), improved granulation tissue formation (HSC, <i>n</i> = 3) and shorter hospitalization time (BM-MNCs; <i>n</i> = 108) compared to standard of care, with no adverse reactions. PI healing rate decreased only in one study with BM-MNC therapy, compared to control (<i>n</i> = 86). Based on the available data, though with limited evidence, it seems that macrophage deployment showed the most favorable outcomes. The results indicate that cell-based therapies offer a potential avenue for enhancing wound healing and tissue repair in PI; however, more extensive research is needed in this domain.</p>\",\"PeriodicalId\":17384,\"journal\":{\"name\":\"Journal of Tissue Engineering\",\"volume\":\"14 \",\"pages\":\"20417314231201071\"},\"PeriodicalIF\":6.7000,\"publicationDate\":\"2023-11-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658773/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Tissue Engineering\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1177/20417314231201071\",\"RegionNum\":1,\"RegionCategory\":\"工程技术\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CELL & TISSUE ENGINEERING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Tissue Engineering","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1177/20417314231201071","RegionNum":1,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0
摘要
严重压伤(PI)的高复发率和并发症需要探索先进的治疗方法,如细胞治疗,以促进伤口愈合。这种技术利用不同细胞类型的能力来促进血管生成、皮肤的再上皮化和组织再生。本系统综述探讨了细胞疗法和组织工程治疗深部PI的疗效。我们在四个在线图书馆(PubMed, Embase, Ovid Medline和Cochrane)中检索了使用细胞治疗成人PI的介入性研究;最近搜索日期为2023年6月10日)。我们发现了一项随机临床试验(RCT),两项非RCT和三项前后研究,包括481名PI患者(253名干预/228名对照)。根据ROBINS-I、NIH和robins -2工具的评估,由于结果测量偏差最小,偏倚风险被分类为中等,由于患者随机化方法不明确,偏倚风险被分类为高。在以细胞为基础的PI治疗的背景下,发现了四种细胞类型:骨髓单核干细胞(BM-MNCs, n = 2);造血干细胞(HSC, n = 1);巨噬细胞和活化的巨噬细胞悬液(AMS, n = 2);低温保存的含有活细胞的胎盘膜(vCPM, n = 1)。在接受细胞治疗的患者中观察伤口愈合结果,包括完全伤口闭合(AMS, vCPM;n = 142),愈合速度更快(BM-MNCs, AMS;n = 146),改善肉芽组织形成(HSC, n = 3)和缩短住院时间(BM-MNCs;N = 108)与标准护理相比,无不良反应。与对照组相比,仅在一项研究中,脑卒中- mnc治疗的PI治愈率下降(n = 86)。根据现有数据,尽管证据有限,但巨噬细胞部署似乎显示出最有利的结果。结果表明,细胞疗法为促进PI的伤口愈合和组织修复提供了一条潜在的途径;然而,这一领域还需要更广泛的研究。
Advancements in cell-based therapies for the treatment of pressure injuries: A systematic review of interventional studies.
The high recurrence and complications associated with severe pressure injuries (PI) necessitate the exploration of advanced treatments, such as cell-based therapies, to facilitate wound healing. Such techniques harness the ability of different cell types to promote angiogenesis, re-epithelialization of the skin, and tissue regeneration. This systematic review explores the efficacy of cell-based therapies and tissue engineering in treating deep PI. We searched for interventional studies using cells in the treatment of PI in adults in four online libraries (PubMed, Embase, Ovid Medline, and Cochrane; latest search 10th June 2023). We found one randomized clinical trial (RCT), two non-RCT, and three pre-post studies, comprising 481 study participants with PI (253 intervention/228 controls). The risk of bias was categorized as moderate due to minimal bias in outcome measurements, or high owing to unclear patient randomization methods, as assessed by the ROBINS-I, NIH, and RoB-2 tools. Four cell types were identified in the context of cell-based therapies of PI: bone marrow mononuclear stem cells (BM-MNCs, n = 2); hematopoietic derived stem cells (HSC, n = 1); macrophages and activated macrophage suspensions (AMS, n = 2); and cryopreserved placental membrane containing viable cells (vCPM, n = 1). Wound healing outcomes were observed in patients undergoing cell-based therapies, including complete wound closure (AMS, vCPM; n = 142), faster healing rate (BM-MNCs, AMS; n = 146), improved granulation tissue formation (HSC, n = 3) and shorter hospitalization time (BM-MNCs; n = 108) compared to standard of care, with no adverse reactions. PI healing rate decreased only in one study with BM-MNC therapy, compared to control (n = 86). Based on the available data, though with limited evidence, it seems that macrophage deployment showed the most favorable outcomes. The results indicate that cell-based therapies offer a potential avenue for enhancing wound healing and tissue repair in PI; however, more extensive research is needed in this domain.
期刊介绍:
The Journal of Tissue Engineering (JTE) is a peer-reviewed, open-access journal dedicated to scientific research in the field of tissue engineering and its clinical applications. Our journal encompasses a wide range of interests, from the fundamental aspects of stem cells and progenitor cells, including their expansion to viable numbers, to an in-depth understanding of their differentiation processes. Join us in exploring the latest advancements in tissue engineering and its clinical translation.